Twice-yearly inclisiran injections halve LDL-cholesterol levels

Nature Reviews Cardiology, Published online: 31 March 2020; doi:10.1038/s41569-020-0373-0The safety and durability of the LDL-cholesterol-lowering effects of inclisiran, a small interfering RNA that inhibits the synthesis of PCSK9 in the liver, have now been confirmed in three phase III clinical trials published in the New England Journal of Medicine.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research